Injectable Platelet-Rich Fibrin (PRF): The newest biomaterial and its use in various dermatological conditions in our practice: A case series
Abstract
Injectable platelet-rich fibrin (I-PRF) is a second generation, fully autologous, blood-derived biomaterial having three-dimensional fibrin meshwork, like that of a PRF clot, while retaining the fluid nature, just like platelet-rich plasma (PRP). Along with platelets and its growth factors, injectable PRF predominantly has collagen type-1, lymphocytes along with its growth factors. Preparation of injectable PRF is simple and requires minimal instrumentation and materials, making it a cost-effective product. We have been trying using this biomaterial in the conditions where PRP and PRF clot are being used currently, like androgenetic alopecia, periorbital rejuvenation, temporary filler material and as an agent to promote wound healing with favorable results.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents
- On model selections for repeated measurement data in clinical studies
- Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells
- Region-specific microRNA signatures in the human epididymis
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.